Peregrine Pharmaceuticals reported $451.22M in Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Agenus AGEN:US USD 429.02M 27.15M
Amgen AMGN:US USD 63.7B 4.41B
AstraZeneca AZN:LN USD 94.18B 2.39B
Biocryst Pharmaceuticals BCRX:US USD 558.59M 48.06M
Bristol Myers Squibb BMY:US USD 98.2B 2.16B
Celldex Therapeutics CLDX:US USD 369.23M 33.74M
Eli Lilly And LLY:US USD 47.46B 397.9M
GlaxoSmithKline GSK:LN GBP 60.31B 28.73B
Immunogen IMGN:US USD 358.8M 63.5M
Intrexon XON:US USD 259.24M 61.98M
Karyopharm Therapeutics KPTI:US USD 231.24M 25.24M
Macrogenics MGNX:US USD 195.35M 22.7M
Mannkind MNKD:US USD 293.84M 8.04M
Minerva Neurosciences NERV:US USD 59.76M 5.2M
Newlink Genetics NLNK:US USD 79.21M 6.24M
Novartis NOVN:VX USD 118.46B 4.45B
Novavax NVAX:US USD 2.27B 355.56M
Peregrine Pharmaceuticals PPHM:US USD 451.22M 21.38M
Repligen RGEN:US USD 2.46B 17.62M
Roche Holding ROG:VX 86.74B 5.58B
Xencor XNCR:US USD 835.27M 16.06M